AndhraNews.net
Home » Features » Health » Pneumonia

Pneumonia


About Pneumonia

Pneumonia is a type of fever.

Bcitracin for injection, USP (bacitracin), an anti-infective product by Sagent Pharmaceuticals is used to treat pneumonia and empyema.

Pneumonia in News

Mesothelioma Victims Center Now Urges a Family That Just Lost a Loved One to Mesothelioma to Call Them for Possible Vital Assistance With Compensation -- Don't Wait -- Time Really Can Run Out
WASHINGTON, DC--(Marketwired - December 03, 2015) - The Mesothelioma Victims Center urges any family grieving over the loss of a loved one to mesothelioma that was unable to begin the compensation process, to call them ASAP as long as it has been less than one year since the diagnosis.

Basilea provides clinical program updates
Basilea Pharmaceutica AG /Basilea provides clinical program updates. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Healthcare Cyber Security Market to Reach $10.85 Billion by 2022: Grand View Research, Inc.
Global healthcare cyber security market size is expected to reach nearly USD 10.85 billion by 2022, according to a new report by Grand View Research, Inc. Key factors attributing to the growth of the market include the increasing incidences of cyber attacks for misuse of electronic patient health records (E-PHR), social security records, IP theft, and others.

Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
Novartis International AG /Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

For Giving Tuesday -- Give the Gift of Sunshine: Solavore's Indiegogo Campaign Funds the Distribution of Solar Ovens in India, Cambodia and Kenya

Eight Aurora Health Care Hospitals Earn Top Honors From The Joint Commission
MILWAUKEE, WI--(Marketwired - November 17, 2015) - Aurora Health Care today announced that eight of its hospitals have been recognized as 2014 Top Performers on Key Quality Measures® by The Joint Commission, the leading accreditor of health care organizations in the United States

Joint Commission Recognizes 1,043 Hospitals for Outstanding Performance on Key Quality Measures
The Joint Commission announces the release today of America's Hospitals: Improving Quality and Safety: The Joint Commission's Annual Report 2015, summarizing data on 49 accountability measures reported by more than 3,300 Joint Commission-accredited hospitals in 2014.

Mesothelioma Victims Center Now Urges Individuals or Family Members of a Loved One Diagnosed With This Cancer to Call Them About the Nation's Top Regional Hospitals for the Best Possible Mesothelioma Treatment
WASHINGTON, DC--(Marketwired - November 16, 2015) - Aside from being the nation's top branded source for the best mesothelioma compensation, the Mesothelioma Victims Center is also known for honest information, such as recommendations for top regional mesothelioma treatment facilities in the nation

BCG's Head of Social Impact, Wendy Woods, Receives 'Women Leaders' Award
Wendy Woods, a senior partner at The Boston Consulting Group (BCG) and global leader of the firm's Social Impact practice, has received a Women Leaders in Consulting Award from Consulting magazine, the industry's premier trade publication. Woods, who is based in Boston, was one of 13 women the magazine recognized last night at a gala dinner at Manhattan's St

Theravance Biopharma, Inc. Reports Third Quarter 2015 Financial Results and Provides Business Update
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the third quarter ending September 30, 2015. Revenue for the third quarter of 2015 was $10.7 million. Net loss for the third quarter of 2015 was $47.3 million, or $1.40 per share. Cash, cash equivalents, and marketable securities, excluding restricted cash, totaled $196

Mesothelioma Victims Center Urges Diagnosed Plumbers and Welders to Call Them About the Qualities Their Lawyer Must Have in Order to Get the Best Financial Settlement -- Don't Get Shortchanged
WASHINGTON, DC--(Marketwired - November 05, 2015) - The Mesothelioma Victims Center is strongly encouraging all plumbers, welders, electricians or construction workers with mesothelioma to call them at 866-714-646 about what qualities a lawyer must have to get the best compensation for this rare cancer

TiGenix: SEPCELL project in severe sepsis receives €5.4M grant from the EU's Horizon 2020
TiGenix is leading the SEPCELL project which aims to accelerate the clinical development of Cx611 in severe sepsis The €5

Mesothelioma Victims Center Now Offers a Reality Check for a Diagnosed Machinist or Skilled Trades Worker -- The Nation's Top Mesothelioma Lawyers Get Much Better Compensation for Their Clients -- Don't Shortchange Yourself
WASHINGTON, DC--(Marketwired - October 29, 2015) - The Mesothelioma Victims Center is now offering a reality check for skilled trades worker such as a plumber or electrician with mesothelioma. The group has information on what lawyers in the nation produce the best compensation results, and urge a diagnosed person or their family to call them anytime 866-714-6466

Immunovaccine's Vaccine Candidate for Respiratory Syncytial Virus Is Well Tolerated in Volunteers in Phase 1 Clinical Trial
Immunovaccine Inc

Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Business Wire India

Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma
Business Wire India

Takeda Reports Five-Year Overall Survival Data for ADCETRIS® (Brentuximab Vedotin) Demonstrate Durable Remissions in Relapsed/Refractory Hodgkin Lymphoma
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE:4502) announced post-treatment follow up data from the pivotal phase 2 study of single-agent brentuximab vedotin for the treatment of relapsed or refractory Hodgkin lymphoma following autologous stem cell transplantation (ASCT)

Takeda to Present Data from Ixazomib’s Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE: 4502) announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015

Five Majors Announce Project ĀSMĀN to Reduce Maternal and New-born Mortality in India

Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
Business Wire IndiaSeattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the companies have achieved completion of target patient enrollment in the phase 3 ECHELON-1 clinical trial

Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parainfluenza Viruses (HPIV), Types 1, 2 and 3

Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia
Basilea Pharmaceutica AG /Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS
Novartis International AG /Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

One Woman's Story: Living and Helping Others With Inherited Lung Disorder
(Family Features) Wheezing, shortness of breath and chronic bronchitis are often associated with asthma or chronic obstructive pulmonary disease (COPD). However, they are also symptoms of a serious genetic form of emphysema called Alpha-1 Antitrypsin Deficiency, also known as Alpha-1.

RxAir Device Destroys Flu Viruses Missed By Vaccines
While the Centers for Disease Control and Prevention (CDC) warned Dec. 4 that the flu vaccine may not be as effective against the serious flu strains that are the most dominant this flu season, the new RxAir® UV air purification system by UV Flu Technologies (OTCBB: UVFT) destroys all types of flu viruses, effectively reducing exposure for everyone in the room, even unvaccinated individuals

Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany
Basilea Pharmaceutica AG /Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

RxAir Germicidal UV Light Air Purifiers Now Available on Amazon Prime, Rakuten.com
The RxAir® Air Purification System with powerful virus and bacteria destroying UV light technology is now available for purchase in two new online locations -- Amazon/Amazon Prime and Rakuten.com. In addition RxAir is available on its own www.RxAir.com website, AirPurifiersAndCleaners.com, GoCPAP.com, SleepRestfully.com and more

John A. Hartford Foundation Forges Public-Private Partnership With CMMI to Spread "Hospital at Home" Model of Care
NEW YORK, NY--(Marketwired - November 13, 2014) - To help improve the health of older adults, the John A. Hartford Foundation has formed a new public-private partnership with the Centers for Medicare & Medicaid Services (CMS) to support testing, delivery, and dissemination of the Mobile Acute Care Team

Joint Commission Recognizes 1,224 Hospitals for Outstanding Performance on Key Quality Measures
Hospitals across the United States continue to improve their rates for complying with evidence-based care processes according to "America's Hospitals: Improving Quality and Safety: The Joint Commission's 2014 Annual Report." The results, released today, are based on data reported by more than 3,300 Joint Commission accredited hospitals in 2013

Theravance Biopharma, Inc. Reports Third Quarter 2014 Financial Results
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today reported financial results for the third quarter 2014. Revenue for the third quarter of 2014 was $6.3 million. Net loss for the third quarter of 2014 was $54.5 million or $1.72 per share

Seegene Introduces Allplex(TM) Assays Based on MuDT(TM) Next-Generation qPCR Technology
Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex PCR technologies, today announced that it is introducing the first three comprehensive Allplex™ assays using its next-generation qPCR technology, called MuDT™

New RxAir(R) Website Details Virus-, Bacteria-Destroying Air Purification Technology
UV Flu Technologies, Inc.'s (OTCBB: UVFT) RxAir® division has launched the new website http://www.RxAir.com featuring RxAir's flagship product, the RxAir Air Purification System

Medicare Costs Analysis Indicates Need for Decreasing Use of Biopsies as Diagnosis Tool for Lung Cancer
CHICAGO, IL--(Marketwired - October 30, 2014) - Biopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Soft Bones Foundation Celebrates Fourth Annual Hypophosphatasia (HPP) Awareness Week
Soft Bones, Inc., an organization dedicated to providing information, education and support to those affected by hypophosphatasia (HPP), is pleased to celebrate the fourth annual HPP Awareness Week and the official HPP Awareness Day, October 30, on the day before Halloween.

Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Seattle Genetics, Inc

Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502) today announced results from an open-label, Phase 2 study evaluating the safety and efficacy of oral, single-agent ixazomib (MLN9708) as maintenance therapy in patients with multiple myeloma (MM) who had received ixazomib, lenalidomide and dexamethasone as induction therapy

Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) has announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)

Healthcare Experts Across India Come Together to Fight Pneumonia Amongst the Older Population of the Country
To commemorate World Pneumonia Day 2014, experts across renowned national institutes have initiated a campaign to spread maximum awareness about the symptoms and causes of Pneumonia among the elderly population in India. This campaign is an effort to protect adults aged 50 years and above from the deadly pneumococcal disease and thereby reduce the rate of death caused due to pneumonia

Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma and Ixazomib in Multiple Myeloma to be Presented at 56th American Society of Hematology Annual Meeting

Micro Imaging Technology Adds Staph Bacteria to Its Catalog of Identifiers
Micro Imaging Technology, Inc. (OTCQB: MMTC) announced that its MIT 1000 System can now identify the potentially life-threatening bacteria Staphylococcus

Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test - AmpliVue(R) Group B Strep Assay
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its AmpliVue Group B Strep Assay

It's Not Too Late to Vaccinate -- Get Your Flu Vaccine Today
WASHINGTON, DC--(Marketwired - December 10, 2013) - "Flu season typically peaks in February and can last as late as May," says Dr. Anne Schuchat, Assistant Surgeon General of the U.S. Public Health Service and Director of CDC's National Center for Immunization and Respiratory Diseases. "We are encouraging people who have not yet been vaccinated this season to get vaccinated now."

Masimo and Newborn Foundation Jointly Announce Mobile Health Initiative to Reduce Global Newborn Mortality
Masimo (NASDAQ: MASI) today announced the launch of iSpO2™ Rx Pulse Oximeter with M-LNCS™ connector, enabling adhesive sensor use on newborns for accurate and cost-effective screening with mobile devices in low-resource settings

GSK and Theravance Announce Positive Results From Pivotal Phase III Study for Fluticasone Furoate/Vilanterol in Asthma
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate "FF"/vilanterol "VI" designed to support a potential filing for an asthma indication for adults in the US.

UPDATE: Tallwave Kicks-off Global Entrepreneurship Week With High Tide for Healthcare IT Startup Competition and Innovation Search
Joining participants across the entrepreneurship spectrum in celebration of Global Entrepreneurship Week (GEW) November 18-24, Tallwave today announced the kick-off of its High Tide for Healthcare IT startup competition and innovation search

RELVAR(R) ELLIPTA(R) Receives European Marketing Authorisation for the Treatment of Asthma and COPD
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has granted marketing authorisation for RELVAR® ELLIPTA®, which is now licensed across 31 European countries for the following uses:

Tallwave Kicks-off Global Entrepreneurship Week With High Tide for Healthcare IT Startup Competition and Innovation Search
Joining participants across the entrepreneurship spectrum in celebration of Global Entrepreneurship Week (GEW) November 18-24, Tallwave today announced the kick-off of its High Tide for Healthcare IT startup competition and innovation search

Official Roster of Teams Announced in the $10 Million Qualcomm Tricorder XPRIZE
XPRIZE today announced the 34 registered teams competing for the Qualcomm Tricorder XPRIZE, a 3.5-year global competition sponsored by the Qualcomm Foundation that will award $10 million to teams that develop a consumer-friendly, mobile device capable of diagnosing and interpreting a set of 15 conditions and capturing vital health metrics

Sage Products Files Patent Infringement Lawsuit Against SwipeSense
CARY, IL--(Marketwired - November 05, 2013) - Sage Products LLC (www.sageproducts.com) announced today that it has filed a lawsuit for patent infringement against SwipeSense, Inc. ("SwipeSense") in the United States District Court for the Northern District of Illinois.

ABLYNX ANNOUNCES UPDATE ON ANTI-RSV NANOBODY PROGRAMME AND RECEIVES GRANT FUNDING FOR FURTHER DEVELOPMENT
GHENT, Belgium, 31 October 2013 - Ablynx [Euronext Brussels: ABLX] today announced that it has received notice of a €1.68 million in grant funding from the Flemish Agency for Innovation by Science and Technology (IWT) to help advance the Company's first inhaled Nanobody®, ALX-0171, in infants

Joint Commission Annual Report Recognizes 1,099 "Top Performer" Hospitals
Thirty-three percent of Joint Commission-accredited hospitals reporting accountability measure data for 2012 are Top Performer hospitals, using evidence-based care processes that are delivered in the right way and at the right time, according to Improving America's Hospitals: The Joint Commission's Annual Report on Quality and Safety 2013.

BREO(R) ELLIPTA(TM) Now Available in the U.S. for the Treatment of COPD
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), is now available to pharmacies throughout the U.S.

Theravance Reports Third Quarter 2013 Financial Results
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the quarter ended September 30, 2013. Revenue for the third quarter of 2013 was $0.4 million. Net loss for the third quarter of 2013 was $47.0 million or $0.44 per diluted share. Cash and cash equivalents, short-term investments and marketable securities totaled $594.5 million as of September 30, 2013.

Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia
Basilea Pharmaceutica AG /Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

ACTIVAERO FURTHER STRENGTHENS CYSTIC FIBROSIS COMPETENCE THROUGH NEW RESEARCH COLLABORATION WITH STANFORD UNIVERSITY
Activaero GmbH /ACTIVAERO FURTHER STRENGTHENS CYSTIC FIBROSIS COMPETENCE THROUGH NEW RESEARCH COLLABORATION WITH STANFORD UNIVERSITY . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Updated Data with Oral Proteasome Inhibitor MLN9708 Reported in Newly Diagnosed Multiple Myeloma Patients
Takeda Pharmaceutical Company Limited (TSE:4502) today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM)

Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Seattle Genetics, Inc

ABRAXANE® Phase III Study of Patients with Metastatic Pancreatic Cancer Published in New England Journal of Medicine

GSK Announces New Rs. 864 crore [£85million] Pharmaceutical Manufacturing Investment in India
A new Rs. 864 crore [£85million] factory creating 250 jobs in India was today announced by healthcare company GlaxoSmithKline (GSK) as part of its continued commitment to ensuring access to medicines for people in the country

Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on VIBATIV(R) (telavancin) for the Treatment of Nosocomial Pneumonia
Theravance, Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) meeting on VIBATIV® (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.

Theravance Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on VIBATIV(R) (telavancin)
Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has posted on its website briefing documents for the November 29, 2012 Anti-Infective Drugs Advisory Committee (AIDAC) meeting

PropThink: Big Catalysts Approaching For Trius Therapeutics
By Jason Napodano, CFAFundamentals at Trius Therapeutics (NASDAQ:TSRX) remain solid. I see the development of tedizolid, current in its second phase 3 trial, as low risk. Data from the first phase 3 trial met all primary and secondary endpoints

Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib and Oprozomib at 54th American Society of Hematology Annual Meeting
Onyx Pharmaceuticals, Inc

13th DCVMN Conference: Bill and Melinda Gates Foundation Applauds Bio Farma
Bill and Melinda Gates Foundation appreciates Indonesia, especially Bio Farma for hosting an esteemed Developing Countries Vaccine Manufacturers Network (DCVMN) Annual General Meeting in Bali from October 31st - November 2nd, 2012. Dr

Onyx Pharmaceuticals Completes Enrollment in FOCUS Phase 3 Carfilzomib Trial in Patients With Relapsed and Refractory Multiple Myeloma
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that the company completed enrollment in the FOCUS trial, an international Phase 3 clinical trial evaluating single-agent carfilzomib in patients with relapsed and refractory myeloma who have received three or more prior therapies

Basilea's European Marketing Authorization Application for ceftobiprole for the treatment of pneumonia accepted for review
Basilea Pharmaceutica AG /Basilea's European Marketing Authorization Application for ceftobiprole forthetreatment of pneumonia accepted for review. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Basilea's European Marketing Authorization Application for ceftobiprole for the treatment of pneumonia accepted for review
Basilea Pharmaceutica AG /Basilea's European Marketing Authorization Application for ceftobiprole for the treatment of pneumonia accepted for review . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Joint Commission Annual Report Names 620 Hospitals as 'Top Performers on Key Quality Measures'
"Improving America's Hospitals: The Joint Commission Annual Report on Quality and Safety 2012," includes 620 hospitals that are leading the way nationally in using evidence-based care processes closely linked to positive patient outcomes

Ablynx's First Inhaled Nanobody Successfully Completes Phase I Study
ALX-0171 has the potential to become a first-in-class therapy Ablynx [Euronext Brussels: ABLX] todayannounced that it has achieved positive results from a Phase I study withthefirst ever inhaled Nanobody, ALX-0171, a trivalent molecule which hasbeenspecifically designed by Ablynx for direct lung delivery, via a nebuliser,totreat respiratory syncytial virus (RSV) infections

ABLYNX'S FIRST INHALED NANOBODY SUCCESSFULLY COMPLETES PHASE I STUDY
ALX-0171 has the potential to become a first-in-class therapy

Basilea reports presentation of new data on investigational anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC
Basilea Pharmaceutica AG /Basilea reports presentation of new data on investigational anti-infectivesisavuconazole, ceftobiprole and BAL30072 at ICAAC. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement. Basel, Switzerland, September 11, 2012 - Basilea Pharmaceutica Ltd

Hospital-Acquired Infections Diagnostics Market Grew 10% in 2011: Kalorama
The growing focus on hospital-acquired infections (HAI) as a driver of costs and negative outcomes is increasing demand for diagnostic products that can help hospitals and nursing homes decide which patients need treatment and possible isolation

MedHOK's 360ACO(R) Positions ACOs to Reduce Hospital Readmissions, Benefit From Shared Savings
Accountable care organizations (ACOs) that deploy 360ACO® from MedHOK, one of the healthcare industry's fastest-growing software companies, are well-positioned to reduce hospital readmissions and meet quality outcomes as required to benefit from shared savings under the Centers of Medicare and Medicaid (CMS) program.

Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis
Novartis International AG /Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

ABRAXANE® Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study

ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract

Policy Makers Join the Call for the Prevention of Atrial Fibrillation-Related Strokes to be Made a National Healthcare Priority

Hilton Worldwide Announces 2011 LightStay™ Sustainability Results
Hilton Worldwide has announced the 2011 results of LightStay™, the company’s proprietary sustainability measurement system. Overall, the program has been a tremendous success with over $147 million in cumulative savings from efficiency projected for hotels reporting through LightStay

Self-proclaimed messaiah Sun Myung Moon dies at 92
Moonies was admitted to the hospital due to Pneumonia

Was Cheetah the chimp really Tarzan's sidekick
Doubts have been raised about the extraordinary age of Cheetah the chimp, who was apparently Tarzan's sidekick in the 1930s movies, and whether he actually ever appeared on screen.

Keeping your teeth clean 'could reduce risk of pneumonia'
Brushing our teeth properly and regularly is known to prevent gum disease, but a new study led by an Indian origin scientist says it can also potentially reduce the risk of pneumonia.

Mould in Christmas trees could make you ill
Traditional pine needle trees could be behind a list of seasonal health complaints including tiredness, wheezing and even insomnia, scientists have suggested.

Key interventions to reduce maternal, newborn and child deaths identified
A three-year study has identified key interventions to reduce maternal, newborn and chills deaths.

George Michael thanks doctors for saving his life after battling pneumonia
An emotional George Michael thanked his doctors vehemently for saving his life on Friday.

Brittany Murphy's mom blames toxic mold for death
Brittany Murphy's mother has claimed that toxic mold found in the Hollywood star's swanky home had killed her daughter and her son-in-law, and now she wants somebody to pay.

'Mash' actor Harry Morgan dies at 96
Harry Morgan, who is best known for playing Colonel Sherman Potter in US TV show 'Mash' from 1975 to 1983 has passed away at the age of 96.

George Michael out of danger and showing 'significant improvement'
George Michael, who was admitted to the hospital after he suffered from pneumonia, has been moved from intensive care after showing signs of recovery.

Ablynx Initiates Phase I Study With ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV)
Ablynx [Euronext Brussels: ABLX] todayannounced that it has initiated a Phase I study in healthy volunteers withALX-0171, the first Nanobody in clinical development to be delivered byinhalation.ALX-0171 is being developed for the treatment of respiratory syncytialviral(RSV) infections.

Graham, Jobs, Winfrey, Obama under consideration for first 'living persons or recently deceased' postage stamp
A tech visionary, a veteran talk show host, two presidents - current and former - a preacher and a baseball player with good attendance are among the people under consideration for the first-ever postage stamp to honor a living or recently deceased American, according to U.S. Postal Service officials not authorized to speak publicly.

Comment on this story

Share